Published May 28, 2019
| Version v1
Patent
Open
Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists
Contributors
Patent applicant:
Description
Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
Files
US10300076.pdf
Files
(1.6 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:56864069c985a4113b541831b37cfcae
|
1.6 MB | Preview Download |
Additional details
Identifiers
- Patent number
- US 10300076 B2
- Patent application number
- US 201715704726 A
- Other
- oai:uchicago.tind.io:6990
Dates
- Patent filed
-
2017-09-14